Transform the Research Landscape
The Amyloidosis Research Consortium (ARC) was founded in 2015 by Isabelle Lousada, an AL amyloidosis patient. The ARC addresses critical needs in clinical trials and related research for the underserved group of systemic amyloid diseases. We have created a collaborative research model to bring together experts in the field to address the challenges that exist in developing diagnostic tools and to carrying out innovative clinical trials.
The Amyloidosis Research Consortium is committed to building collaborative relationships between patients, academia, industry, foundations, federal funders, and regulators to advance the best research and speed new therapies to market.
The Amyloidosis Research Consortium is focused on increasing the amount of research and building a prioritized portfolio of translational research and clinical research.
Our aim is to address the urgent, unmet medical needs in amyloidosis.
To accelerate the development of advanced diagnostic tools and effective treatments for systemic amyloidosis through collaboration and innovation.